000			02056nam a2200445 i 4500
999			_c278357 _d278357
001			on1080339765
003			OCoLC
005			20190122124209.0
006			m o d f
007			cr bn||||a||||
008			181228s2018 dcuo ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1019-C-01 (online)
086	0		_aY 4.C 73/8:115-60
088			_aSerial no. 115-60 (United States. Congress. House. Committee on Energy and Commerce)
099			_aY 4.C 73/8:115-60
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Health,
245	1	0	_aExamining patient access to investigational drugs : _bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session. October 3, 2017.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_a1 online resource (iv, 235 pages) : _bphotographs
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_a"Serial No. 115-60."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource, PDF version; title from title page (govinfo, viewed Dec. 27, 2018).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tExamining patient access to investigational drugs _w(OCoLC)1080582537
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo113883
050		4	_aKF27 _b.E553 2017o
610	1	0	_aUnited States. _bFood and Drug Administration.
650		0	_aClinical trials _zUnited States.
650		0	_aClinical trials _xMoral and ethical aspects _zUnited States.
650		0	_aDrugs _zUnited States _xTesting.
650		0	_aDrugs _xTesting _xMoral and ethical aspects _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8